Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $13.6250.

VNDA has been the subject of a number of research analyst reports. HC Wainwright increased their price objective on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Zacks Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 11th. Jefferies Financial Group lifted their price objective on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a research note on Wednesday, December 31st. Wall Street Zen downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several large investors have recently added to or reduced their stakes in VNDA. Torren Management LLC purchased a new position in Vanda Pharmaceuticals in the 4th quarter valued at approximately $25,000. Russell Investments Group Ltd. raised its stake in shares of Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares in the last quarter. CWM LLC raised its stake in shares of Vanda Pharmaceuticals by 424.6% in the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 7,575 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Vanda Pharmaceuticals by 3,010.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 10,055 shares during the period. Finally, Jain Global LLC acquired a new position in Vanda Pharmaceuticals during the 4th quarter worth $94,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Stock Down 2.7%

Shares of NASDAQ:VNDA opened at $6.03 on Thursday. The company has a market capitalization of $356.43 million, a price-to-earnings ratio of -1.62 and a beta of 0.62. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.60. The business has a 50-day moving average price of $7.34 and a 200 day moving average price of $5.73. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The company had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. Sell-side analysts expect that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.